Bleomycin Sulfate

For research use only.

Catalog No.S1214 Synonyms: NSC125066

36 publications

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 357 In stock
USD 170 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bleomycin Sulfate has been cited by 36 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm5SlhjOOLCk{GwNFAh|ryv MnS3NlQhcMLi M{S3R4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{LGdVI3ODh6N{Gx
POLK WT MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP NULONmtXOjZyM{G0NFA>
POLK KO NWe3TVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXTd3ZKSzVyPUSuNFPjiIoEsfMAjVEvQTMEoN88US=> NHX2T3gzPjB|MUSwNC=>
POLK CD MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTxTWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= MXqyOlA{OTRyMB?=
RLE/Abca3 M3\zTGZ2dmO2aX;uJGF{e2G7 MU[wMlTDqM7:TR?= NIjJTlEyPDUEoHi= MUfpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi NIH3fJQzPTd4MEWzPC=>
PMCs NEnQXpZHfW6ldHnvckBCe3OjeR?= MWqwMlHjiJN{wrFOwIcwdWx? MV[yOOKhcA>? M2\zboNifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;0[YlvKGyndnXsJI9nKGOxbHzh[4VvNUoEoB?= MojTNlU2QTV4NEK=
PMCs MVzGeY5kfGmxbjDBd5NigQ>? NIjzbGIxNjMEoN88[{9udA>? NH;XdFczPOLCk{eyxsBp MkjYbY5lfWOnczDpcoNz\WG|ZYOgbY4hfmmvZX70bY4h[W6mIN8xMXNOSSCycn;0[Ylv MmfYNlU2QTV4NEK=
PMCs MlrqSpVv[3Srb36gRZN{[Xl? Mlv5NE4zyqEQvHevcYw> NVHlfGtFPzJiaB?= MlKxbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv M3qxXVI2PTl3NkSy
PMCs NXHxWIpqTnWwY4Tpc44hSXO|YYm= MXiwMlLDqM7:Zz;tcC=> NHXweIcyOi9{ND:0PEBp MWTpcoNz\WG|ZYOgZ4VtdCCvaXfyZZRqd25? NYLPNGgzOjV3OUW2OFI>
IMR-32 M1\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3joSVcvPeLKkkGyNEDDvWdxbXy= M1y5SVEz6ojUNEigbC=> NEH5WXZKSzVyPU[wJOK2\y:vbDDheEB1cGViZX7kJI9nKDJ2IHjyd{Bw\iCrbnP1ZoF1cW:w MXmyOVU{PjN2NR?=
HT1080 M2PL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W5[lEh|ryP NY\zSYttOjRiaNMg NVvpZXl{dGWjZIOgeI8h[SCJMj;NJIRmdGG7 MWiyOVUyQDl4MR?=
HT1080 NFPld4ZHfW6ldHnvckBCe3OjeR?= NX\DN3g4OSEQvF2= NGq1fWwzPCCqwrC= MoPGbY5lfWOnczDhJJBwfGWwdDDncI9j[WxiRF7BJIRidWGpZTDy[ZNxd26|ZR?= NELlWIwzPTVzOEm2NS=>
HDFn MXPDfZRwfG:6aXPpeJkhSXO|YYm= MmWwO|IhcA>? M1LtcmlEPTB;OT6zNUXDqA>? M3PLcFI2Ojd4N{my
THP-1 NUXsfIE1S3m2b4TvfIlkcXS7IFHzd4F6 MXK3NkBp NXLZUZJVUUN3ME20Mlc4LQ>? MVyyOVI4Pjd7Mh?=
HT-29 MYLDfZRwfG:6aXPpeJkhSXO|YYm= NV3xXnBIPzJiaB?= Mn;BTWM2OD1zMT60PUU> MkS4NlUzPzZ5OUK=
HCT116  Ml;1R5l1d3SxeHnjbZR6KEG|c3H5 MojQO|IhcA>? M3nWVWlEPTB;MUGuN|Qm NILYU4UzPTJ5Nke5Ni=>
A431 M3XEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmxeYtYPTBvMkCwJGlW M4TvW|Q56oDLaB?= M3rSVolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> Mn7vNlUyODF{OUm=
T24 M3PIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q2TVUxNTJyMDDJWS=> MUK0PQKBkWh? NIHuZWNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MWmyOVExOTJ7OR?=
AY-27  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\LbJVvPTBvMkCwJGlW NXPIXGlpPDkkgJno MnjSbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWSyOVExOTJ7OR?=
A549 M1u5OmZ2dmO2aX;uJGF{e2G7 M3HYfVEhyrWpL33MxsA> MU[wMVQ5KGh? Mk[5bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> MoXENlQ6PjN4M{W=
MLE12 Mn\sSpVv[3Srb36gRZN{[Xl? NGHuXpYyKML3Zz;tUOKh NHTYVFkxNTR6IHi= M2fjOYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C M17HVFI1QTZ|NkO1
Jurkat M1nlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzjNlDjiIoQvH2= MoKwNlTjiImqwrC= M2j2cYFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm NX;sSlg{OjR7MU[4PVM>
HeLa  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW1TphKSzVyPUGwMlLDqM7:TR?= MUGyOFc{OjN7Nx?=
C18-4 NFTCR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPJe3hXOC1zMECg{txO NX;BRnBxcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mk\tNlQ2PzF7OEK=
BMG-1  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;LZpg1OC96MNMg{txoN21? MXGzxsBp MYXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmrnNlM6ODZ5Mk[=
A459 MUDBdI9xfG:|aYOgRZN{[Xl? M13kfFExKG2X MUS0PEBp NXfocXdHcW6mdXPld{BieG:ydH;zbZM> NIjoNlgzOzlyMke2Oi=>
MOCK MWjBdI9xfG:|aYOgRZN{[Xl? MmXKNVAhdVV? MlHVOFghcA>? M2e4colv\HWlZYOgZZBweHSxc3nz NHu2bpYzOzlyMke2Oi=>
MMP1 MWPBdI9xfG:|aYOgRZN{[Xl? NXzuOmhZOTBibWW= NXjQdWZiPDhiaB?= MnrBbY5lfWOnczDhdI9xfG:|aYO= MUCyN|kxOjd4Nh?=
A549 M3Hobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4UWZXOjByIN88US=> NGroe20zPCCqwrC= M1OyeoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MoOxNlM5ODV5OUO=
HCT-116 NF3UcWlCeG:ydH;zbZMhSXO|YYm= NV\WVW5EOy95LkWvNVUh|rypL33s Mnz5OFghcA>? Ml3mdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NUnGR3R{OjN5MEi2Olg>
HeLa MXfBdI9xfG:|aYOgRZN{[Xl? NFTofmI{NzdwNT:xOUDPxGdxbXy= M3n1dlQ5KGh? NWDNc3NJemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? NEC5blgzOzdyOE[2PC=>
HCT116 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fB[lAuOTByIN88[{9udA>? MVS0PEBp M{K4VolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3TNc|I{PTF6MkCx
NCM460 M4HqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHKNE0yODBizsznM41t MYi0PEBp MYjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MnSyNlM2OTh{MEG=
NT2  NFHKeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn4T|kzPCCqwrC= NIm3VHZNTDVyPUSwNQKBkcL3Zz;tcC=> MXeyN|M5PjR{MB?=
NT2  Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLYd|JbPDhiaB?= MV\MSFUxRTFyMDFCuYcwdWx? MoTxNlM{QDZ2MkC=
NT2  NXHQV5VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7GTm9GPzJiaB?= Mk\kUGQ2OD1{MPMAjeK2\y:vbB?= M2XvXlI{Ozh4NEKw
NT2  M1[wWWFxd3C2b4Ppd{BCe3OjeR?= MX20NFDjiIoEtXevcYw> M2HaUlI1KGkEoB?= MYrpcoR2[2W|IIPp[45q\mmlYX70JIlv[3KnYYPld{BqdiClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> MmLONlM{QDZ2MkC=
NTera-2 MkfXSpVv[3Srb36gRZN{[Xl? M4HVOFEzOCEQvHevcYw> MlewO|IhcA>? M2W5fZNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz MWGyNlgzPTN3NR?=
NCCIT M4DifWZ2dmO2aX;uJGF{e2G7 Ml7KNVIxKM7:Zz;tcC=> NUC0VodPPzJiaB?= NWrTSXlWe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> MXiyNlgzPTN3NR?=
NTera-2 NUDxc3BsTnWwY4Tpc44hSXO|YYm= NGDxcmoyOjBizsznM41t MmrtO|IhcA>? NIjSVnV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MmXjNlI5OjV|NUW=
NCCIT Mk\xSpVv[3Srb36gRZN{[Xl? MU[xNlAh|rypL33s MnL6O|IhcA>? NILSVoh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> NGXZeGczOjh{NUO1OS=>
NCCIT NV\UXXBqTnWwY4Tpc44hSXO|YYm= NYD4U5pkOTJyIN88[{9udA>? M3WydFczKGh? MnX4d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= NEDTcZMzOjh{NUO1OS=>
NTera-2 MX7GeY5kfGmxbjDBd5NigQ>? M4nNZ|EzOCEQvHevcYw> NEjGWVQ4OiCq Moqxd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MmTFNlI5OjV|NUW=
NCCIT MlvISpVv[3Srb36gRZN{[Xl? MlzFNVIxKM7:Zz;tcC=> NWXLRZd3PzJiaB?= M{fsZpNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ MoK3NlI5OjV|NUW=
NTera-2 MkHzSpVv[3Srb36gRZN{[Xl? NWL4cHFYOTJyIN88[{9udA>? M{Pne|czKGh? NYTLZ|NRe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> M4\MdlIzQDJ3M{W1
NCCIT MWXGeY5kfGmxbjDBd5NigQ>? MY[xNlAh|rypL33s NWXKfnBZPzJiaB?= MnPZd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= NFfyN2gzOjh{NUO1OS=>
MDA-MB-468 NWH2eJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD3NQKBmzJyMNMg{txoN22O M1rZT|I1KGh? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NVXCT2hvOjJ6MUmxPVY>
231-H2N MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmw5qCUOjBywrFOwIcwdUx? NUntXmFsOjRiaB?= NF;UdXdqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{HJZVIzQDF7MUm2
A549  M2jHS2Z2dmO2aX;uJGF{e2G7 M1\PT|IxOC92MECg{txO MVHy[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= NIG2c2czOjd5M{[5Oy=>
A549  NHXVeoNHfW6ldHnvckBCe3OjeR?= NX\FeJZ4OC12MECg{txO NELuUmgzNTR6IHi= M2XMfYNifXOnczDtc5JmKG22RF7BJJRp[W5iblTORUBl[W2jZ3W= MkfyNlI4PzN4OUe=
A549  NFrmTW5HfW6ldHnvckBCe3OjeR?= M3;Be|ExOCEQvF5CpC=> NG[4VXMx6oDVNEigbC=> NF[5Vmpk[XW|ZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> MUiyNlc4OzZ7Nx?=
A549  NF7YWWtHfW6ldHnvckBCe3OjeR?= NGPX[|cyODBizszNxsA> NF\ReJox6oDVNEigbC=> M4fDSoNifXOnczDQT2QyKGOuZXH2ZYdm M2jwWFIzPzd|Nkm3
A549  NXnnZnlsTnWwY4Tpc44hSXO|YYm= NWmwWWM3OTByIN88UeKh NH7xXWgx6oDVNEigbC=> NIfkdmlk[XW|ZYOgcYl1d2Oqb37kdolidCCub3PhcIl7[XSrb36gc4YhSmG6 MX6yNlc4OzZ7Nx?=
A549  MXfGeY5kfGmxbjDBd5NigQ>? NVLCVpZnOTByIN88UeKh MlnkNQKBmzR6IHi= MV\k[YNz\WG|ZYOgUW1RKGGwZDDBWHAhdGW4ZXzz Mlq2NlI4PzN4OUe=
MCF-7/Her-18  NYPEZYdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWwMlQzNTF5MECg{txoN22O MXWyOEBp M4nIe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3fJclIzPjJzNEC0
MCF-7 MX;QSHQwWEOLIGTy[YF1dWWwdB?= MoL0NE4zPSEQvHevcYwv MV6xMVQhcA>? NIHWWmJ{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NUTV[2lROjJ3OUGyPFQ>
MDA-MB-231 Mlu2VGRVN1CFSTDUdoVifG2nboS= M1TWb|AvOjVizsznM41tNg>? MluwNU01KGh? MWLzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 NWC2bpVuOjJ3OUGyPFQ>
MDA-MB-235  M{\0dnBFXC:SQ1mgWJJm[XSvZX70 NFfJfXAxNjJ3IN88[{9udC5? NW\6cFdZOS12IHi= MlPTd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> NV;KW2hjOjJ3OUGyPFQ>
MCF-7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPKfpoxNTJizsznM41tNg>? M4H2OlI1NzR6IHi= NF7kcoZGSzVyPUGuNkDPxGdxbVy= M{LnRVIzPTlzMki0
NCCIT  NV;Zb|hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLobVUzOOLCk{G0NOKh|rypL33s NVWzPHVkPzJiaB?= MlLLUGQ2OD1zMkFCpO69\y:vbNMg NHz3OWwzOjV4MkG2NC=>
NCCIT  M4nGcWZ2dmO2aX;uJGF{e2G7 NWHic5Z{PzJiaB?= NHrtcVd{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=> M{DlR|IzPTZ{MU[w
NCCIT  NXjNNmhqTnWwY4Tpc44hSXO|YYm= MnfYO|IhcA>? MVzzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNThiYXP0bZZqfHoEoB?= NX[xUXEzOjJ3NkKxOlA>
NCCIT  M4\POmZ2dmO2aX;uJGF{e2G7 NXu4c2FmPzJiaB?= NUf6Omlje2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT25JIFkfGm4aYT5xsA> NEfQN4UzOjV4MkG2NC=>
NCCIT  MX;GeY5kfGmxbjDBd5NigQ>? NH7MSmE4OiCq MmXod4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu MV:yNlU3OjF4MB?=
NCCIT  M3LaeGZ2dmO2aX;uJGF{e2G7 Mme5O|IhcA>? MYPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgRoNtNTJiY3;ueIVvfA>? M{TMR|IzPTZ{MU[w
NCCIT  NX\oXnJ6TnWwY4Tpc44hSXO|YYm= NGHxfJU4OiCq Mk\Hd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt MlTjNlI2PjJzNkC=
HeLa M3zuR2Z2dmO2aX;uJGF{e2G7 Mn;lN|AwPzBizsznM41t NYPnSGtpOjUEoHi= MYPpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> MYiyNlQ5Pzl|Nx?=
MCF-7  M3TvdGZ2dmO2aX;uJGF{e2G7 NH;6SJE{OC95MDFOwIcwdWx? MVSyOOKhcA>? MVrpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> NIHac|IzOjR6N{mzOy=>
HeLa NFHhXYpEgXSxdH;4bYNqfHliQYPzZZk> NXnRNZRPOzBxN{Cg{txoN22u MYWyOOKhcA>? NYTLcJNJcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt MVKyNlQ5Pzl|Nx?=
MCF-7  MnH3R5l1d3SxeHnjbZR6KEG|c3H5 MonZN|AwPzBizsznM41t NEPDOG4zPMLiaB?= MY\pcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? M3nmVlIzPDh5OUO3
NT2 NH7qNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXWbYVNOTByLU[wNOKh|rypL33s NVvLPJUyOjRiaB?= MUfJR|UxRTRyMDFCuYcwdWx? NI\0c2gzOjR4OUm1Ni=>
NT2 NWjUSWJ7TnWwY4Tpc44hSXO|YYm= M{Hy[lQxOMLizsznM41t MV:yOEBp NWTabYhze2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi Mmi1NlI1Pjl7NUK=
NT2 NIPNfmRHfW6ldHnvckBCe3OjeR?= MVm0NFDDqM7:Zz;tcC=> MXSyOEBp M1W3W5Nq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= M1PyNVIzPDZ7OUWy
NT2 Mm\rSpVv[3Srb36gRZN{[Xl? MYG0NFDDqM7:Zz;tcC=> NI\pcVQzPCCq MVfzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= NGG0WGgzOjR4OUm1Ni=>
CHO NGPyRZRHfW6ldHnvckBCe3OjeR?= MlHUNk42yqEQvHevcYw> M3XZO|E5KGhxNjDk MofTbY5lfWOnc9MgdIVze2m|dHXuZ4Uhd2ZiY3jyc41we2:vZTDkZY1i\2V? NVzDOph5OjJ{M{CxPVU>
Jurkat NH7CWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXy[5UxNTFyMNMg{txoN22u MkLwNlQhcA>? MWjhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> MXeyNlIzOzN|Mh?=
Jurkat NXfzc4hDTnWwY4Tpc44hSXO|YYm= MUWzNOKh|rypL33s M3jRelI1KGh? MmTZbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCleXPsbY5{KER|LDDBJIFv\CCEMR?= MmXiNlIzOjN|M{K=
Jurkat NFnXZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr1NE0yODEEoN88[{9udA>? NF\BU2UzPCCq MXXpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? NIPUUWMzOjJ{M{OzNi=>
Jurkat NIC0bWRHfW6ldHnvckBCe3OjeR?= NIDYTno{OMLizsznM41t NETZZYozPCCq MlHVbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? M4jvRlIzOjJ|M{Oy
U2OS EGFPnls M1;N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\Pb20xNTMEoN88[{9udA>? MWOyOEBp NUPE[VdmcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NFPmVGQzOThzMUCwOy=>
U2OS KuEnls NWnuOXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELxbYUxNTMEoN88[{9udA>? NUXofVlLOjRiaB?= MYLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NH2ycYEzOThzMUCwOy=>
MCF-7 NYXzcJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXCO4F4OC12MECg{txO NIjn[XU4OiCq NWf3VI1YVEN3ME2xOVEvQMLizszN MXyyNVcxOzJ7MR?=
MCF-7/Adr  M4SyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVyxbJczOC12MECg{txO MXO3NkBp NXi5bmJvVEN3ME21PE42yqEQvF5CpC=> MY[yNVcxOzJ7MR?=
WI-38 M2KxO2Z2dmO2aX;uJGF{e2G7 MWewM|QxNzhy4pEJ{txoN22uwrC= M17LeVMhcA>? NEP3ZoVqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MX[yNVU6QTZzMh?=
hBMSC MljVSpVv[3Srb36gRZN{[Xl? NV\3UHg{OC92MD:4NQKBkc7:Zz;tcOKh MkG1N{Bp NXr4eY1QcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M{m5SlIyPTl7NkGy
NCI-H23 MYfGeY5kfGmxbjDBd5NigQ>? NIXGW|cxNzRyL{iw5qCK|rypL33sxsA> MlH5N{Bp MVLpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NUnG[5FZOjF3OUm2NVI>
A-549 MXnGeY5kfGmxbjDBd5NigQ>? MmnFNE81OC96MPMAje69\y:vbNMg Mm[4N{Bp MojEbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NH;wTVMzOTV7OU[xNi=>
PBL  Mn\WSpVv[3Srb36gRZN{[Xl? NFfHVHYxNzRyL{iw5qCK|rypL33sxsA> NVPKVoZHOyCq M3e5dolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NF7IelUzOTV7OU[xNi=>
pol β −/− NETTe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILxe2oxNjJ3LUKwNOKh|rypL33s M2K1PFI1yqCq NETrcYdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NWLTZ|dkOjF{NUG5OFQ>
pol β +/+ NVjGUXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LaV|AvOjVvMkCwxsDPxGdxbXy= M1\YVFI1yqCq M3Hw[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bZRpKGmwY4LlZZNqdmdiY3;uZ4VvfHKjdHnvcpPDqA>? NW\4OVR[OjF{NUG5OFQ>
pol β −/− Mm\0SpVv[3Srb36gRZN{[Xl? NFPteIkxNTJwNTFOwIcwdWx? NGHuS2QzKGh? NX3WS|Nq[2G3c3XzJGRPSSCmYX3h[4U> NVHLNmZ[OjF{NUG5OFQ>
pol β +/+ M1HxTmZ2dmO2aX;uJGF{e2G7 MkXpNE0zNjVizsznM41t M1\nPVIhcA>? MVHjZZV{\XNiRF7BJIRidWGpZR?= M{ezZlIyOjVzOUS0
pol β −/− NYLUPFRGTnWwY4Tpc44hSXO|YYm= M2frVVAuPSEQvHevcYw> NVvuWGxYPDhiaB?= MkfnZ4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NUfnOHZrOjF{NUG5OFQ>
pol β +/+ M{T1RWZ2dmO2aX;uJGF{e2G7 NIj2SmExNTVizsznM41t MXq0PEBp NYjobWdo[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NFXEWZAzOTJ3MUm0OC=>
TK6  MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGyOU0yPTBizsznM41t MWK5OkBp Mn7qbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFewZ20zOTB6MUS4Oy=>
TK6  sLUC+Apn1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy5TlkzPS1zNUCg{txoN22u MV[5OkBp M1fFUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MV2yNVA5OTR6Nx?=
TK6 sAPE1+Apn1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HEflI2NTF3MDFOwIcwdWx? NIrvc5I6PiCq MkTmd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 MWqyNVA5OTR6Nx?=
HCT116 NV60eWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn4bZd3OjVvMUWwJO69\y:vbB?= NUnYfolGQTZiaB?= M1OwbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MX[yNVA5OTR6Nx?=
HCT116 sLUC+Apn1 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z2dFI2NTF3MDFOwIcwdWx? Ml31PVYhcA>? MoXDbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MXGyNVA5OTR6Nx?=
HCT116 sAPE1+Apn1 M33RTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfzXJQzPS1zNUCg{txoN22u NV\zOVRGQTZiaB?= M3fBXJNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= M3X5RVIyODhzNEi3

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD-1 mice
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066
Smiles CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)C1=C(C)C(=NC(=N1)C(CC(N)=O)NCC(N)C(N)=O)N)C(OC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(OC(N)=O)C3O)C4=C[NH]C=N4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.O[S]([O-])

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID